Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) tinted loss of -2.27% (-0.08 points) to US$3.44. The volume of 0.53 Million shares climbed down over an trading activity of 1.23 Million shares. EPS ratio determined by looking at last 12 month figures is -0.86. Over the same time span, the stock marked US$10.54 as its best level and the lowest price reached was US$2.36. The corporation has a market cap of US$192.02 Million.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)’s earnings per share has been growing at a -22.3 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -65.6 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 64.4 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.57. 4 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Achaogen, Inc. (NASDAQ:AKAO) is worth US$66.9 Million and has recently risen 11.97% to US$1.59. The latest exchange of 1.13 Million shares is above its average trading activity of 1.09 Million shares. The day began at US$1.54 but the price moved to US$1.54 at one point during the trading and finally capitulating to a session high of US$1.58. The stock tapped a 52-week high of US$15 while the mean 12-month price target for the shares is US$7.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.58, and a price to sales ratio of 7.78. For the past 5 years, the company’s revenue has grown -9%, while the company’s earnings per share has grown -22.2%. With an institutional ownership near 50.4%, it carries an earnings per share ratio of -3.96.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 8 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.78.